Lower-dose niraparib to reduce interruptions in ovarian maintenance
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests whether a different starting dose (and adjustments) of niraparib can help people with advanced ovarian (or related) cancer stay on treatment without as many dose interruptions. It’s designed for people who have already finished first-line chemotherapy and whose cancer responded.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can understand the study and sign written consent.
- You are a woman age 18 or older with newly diagnosed high-grade ovarian (or primary peritoneal/fallopian tube) cancer.
- Your cancer is stage III or IV, and you completed at least 4 cycles of platinum chemotherapy, with a good response (no lasting tumor lesion over 1 cm).
- You started chemotherapy-to-study transition within 12 weeks after finishing chemotherapy, and your CA-125 blood marker meets the trial’s response rules.
- You can take pills by mouth and will do frequent blood tests (before cycle 1, then weekly for the first month).
- You’re post-menopausal (or have surgery to prevent pregnancy) or you agree to strong birth control; pregnancy must be ruled out before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the drug niraparib works as a maintenance treatment for women with advanced ovarian cancer that responded well to initial platinum-based chemotherapy. It may help keep the cancer from coming back.
This study looks at how well niraparib works as maintenance therapy for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have already responded to initial chemotherapy. It aims to gather real-world data on the treatment's effectiveness and safety.
This trial is testing a second course of niraparib (a PARP inhibitor) after surgery for ovarian cancer that has come back in just a few spots. It aims to see if restarting niraparib can help keep the cancer from coming back again.
This trial tests whether taking niraparib (a maintenance anti-cancer pill) for a shorter time after 3 cycles of platinum chemotherapy works as well as taking it after 6 cycles. It is for people with advanced ovarian cancer that has been fully removed (no visible tumor) and is “HRD-positive,” meaning it has certain DNA repair weaknesses.
This trial studies whether niraparib works better when combined with bevacizumab after chemotherapy and surgery for advanced ovarian, fallopian tube, or peritoneal cancer. If you qualify, you may help researchers find a treatment plan that controls the cancer for longer.
This trial tests a combination of two targeted drugs, niraparib and abemaciclib, for people with ovarian, fallopian tube, or primary peritoneal cancer that has come back after at least two prior chemotherapies. It may be an option if you have no standard treatments left and your cancer still responds to platinum-based chemotherapy.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.